[1]叶 敏,张风琴,岳发英.氟桂利嗪对偏头痛患者血清环氧合酶2、溶血磷脂酸水平影响及疗效分析[J].陕西医学杂志,2019,(4):524-527.
　YE Min,ZHANG Fengqin,YVE Faying.Flunarizine for migraine serum COX2, impact analysis and effect of LPA level[J].,2019,(4):524-527.
点击复制

氟桂利嗪对偏头痛患者血清环氧合酶2、溶血磷脂酸水平影响及疗效分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年4期
页码:
524-527
栏目:
药物与临床
出版日期:
2019-04-05

文章信息/Info

Title:
Flunarizine for migraine serum COX2, impact analysis and effect of LPA level
文章编号:
DOI: 10.3969/j.issn.10007377.2019.04.034
作者:
叶 敏; 张风琴; 岳发英
湖北省十堰市太和医院疼痛科（十堰 442000）
Author(s):
YE Min; ZHANG Fengqin; YVE Faying
Department of Pain, Taihe Hospital, Shiyan City, Hubei Province(Shiyan 442000)
关键词:
氟桂利嗪; 头痛宁; 偏头痛; 血清环氧合酶2; 溶血磷脂酸; 睡眠质量
Keywords:
Key words Flunarizine; Headache ning; Migraine; Serum cyclooxygenase2; Lgsophosphatidic acid; Sleep quality
分类号:
R747.2
文献标志码:
A
摘要:
摘 要 目的：分析氟桂利嗪对偏头痛者血清环氧合酶2（COX2）、溶血磷脂酸（LPA）水平及疗效影响。方法 ：收治的偏头痛113例，采用随机数字法分为对照组和观察组。对照组患者采用头痛宁治疗，观察组患者采用头痛宁联合氟桂利嗪治疗，两组均治疗4周，观察两组患者治疗前后各项症候评分变化、睡眠质量评分情况、脑血流速度水平、基质金属蛋白酶（MMP9）、COX2、血浆5羟色胺（5HT）及LPA水平变化情况。结果： 两组患者治疗后头痛发作次数、头痛程度、头痛持续时间及头痛伴随症状评分均较治疗前改善，观察组患者治疗后各项症候评分均优于对照组（P<0.05）。两组患者治疗后MMP9、COX2及LPA水平均较治疗前下降，5HT水平较治疗前上升（P<0.05）。观察组患者治疗后各血清因子水平均优于对照组（P<0.05）。两组患者治疗后脑血流速度MCA、ACA及PCA水平均较治疗前下降，观察组患者治疗后脑血流速度水平均较对照组平稳（P<0.05）。两组患者治疗后睡眠质量评分均较治疗前改善， 观察组患者治疗后睡眠质量评分优于对照组（P<0.05）。结论： 氟桂利嗪联合头痛宁治疗偏头痛疗效显著，可降低患者血清MMP9、COX2及LPA水平，平稳患者脑血流速度，提高患者睡眠质量。
Abstract:
Abstract Objective:To analyze the effect of flunarizine on serum cyclooxygenase2 and lysophosphatidic acid (LPA) levels in patients with migraine.Methods:From October 2014 to December 2016, 113 cases of migraine were randomly divided into control group and observation group. The control group was treated with Toutongning treatment, observation group were treated by Toutongning combined with flunarizine treatment, two groups were treated for 4 weeks. To observe the changes of the symptom score of two groups before and after treatment, the score the sleep quality, the level of cerebral blood flow velocity,matrix metalloproteinase (MMP9), COX2, 5 in plasma serotonin (5HT) and the changes of the level of LPA.Results:Two groups of patients after treatment of headache episodes, headache degree, headache duration of headache and accompanying symptoms score were improved compared with before treatment, patients in the observation group after treatment the symptom scores were better than the control group (P<0.05). The two groups of patients after treatment of MMP9, COX2 and LPA level were decreased before treatment, 5HT levels of treatment increased (P<0.05). Patients in the observation group after treatment the serum cytokine level were better than the control group (P<0.05). The two groups of patients after treatment of MCA, ACA and PCA levels were lower than that before treatment, the patients in the observation group were higher than those of the cerebral blood flow velocity The sleep quality scores of the two groups after treatment were better than those before the treatment, and the sleep quality scores of the observation group after treatment were better than those of the control group (P<0.05). (P<0.05).Conclusion:Flunarizine combined with Toutongning treatment of migraine curative effect, can reduce serum MMP9, COX2 and LPA levels in patients with stable, cerebral blood flow velocity, improve the sleep quality of the patients.

参考文献/References:

[1] 沙娟娟, 靳爱相, 姚 力. 氟桂利嗪联合低频重复经颅磁刺激治疗偏头痛46例[J]. 陕西医学杂志, 2016, 45(6):744-745.
[2] Diener HC, Holle-Lee D, Ngel S, et al. Headache Treatment[J]. Deutsche Medizinische Wochenschrift, 2017, 142(6):418.
[3] Mitsikostas DD, Rapoport AM. New players in the preventive treatment of migraine[J]. BMC Medicine, 2015, 13(1):279.
[4] Krymchantowski AV, Jevoux CDC. The pharmacological treatment of migraine in brazil[J]. Headache, 2015, 55(S1):51.
[5] 王纪佐. 国际头痛学会的头痛第二版简介和临床应用[J]. 中国医刊, 2006, 41(12):11-14.
[6] Van OA, Van RV, Van d HP,et al. Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness.[J]. Otology & Neurotology, 2015, 36(1):133-8.
[7] Kuttapitiya A, Harrison A, Assi L,et al. Elation of synovitis, effusions, bone marrow lesions and cartilage damage to pain sensitisation in people with knee osteoarthritis presenting for total knee replacement: an observational study[J]. Annals of the Rheumatic Diseases, 2015, 82(24):1247-9.
[8] Cerritelli F, Ginevri L, Messi G,et al. Clinical effectiveness of osteopathic treatment in chronic migraine: 3-Armed randomized controlled trial.[J]. Complementary Therapies in Medicine, 2015, 23(2):149.
[9] Amundsen S, Nordeng H, Stovner LJ,et al. Pharmacological treatment of migraine during pregnancy and breastfeeding[J]. Nature Reviews Neurology, 2015, 11(4):209.
[10] 屈箫箫, 邵 娣, 杨开洋. 经皮耳迷走神经刺激预防性治疗偏头痛的临床疗效观察[J]. 陕西医学杂志, 2017, 46(9):1255-1257.
[11] Teigen L, Boes CJ. An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine.[J]. Cephalalgia, 2015, 35(10):912-22.
[12] Pringsheim T, Davenport WJ, Marmura MJ,et al. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine[J]. Headache, 2016, 56(7):1194-1200.
[13] Silberstein SD. Considerations for management of migraine symptoms in the primary care setting[J]. Postgraduate Medicine, 2016, 128(5):523-537.
[14] Zdravko L Boris F, Matak I, et al. Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches[J]. British Journal of Pharmacology, 2016, 173(2):279.
[15] Tfelt-Hansen P, Agesen FN, Pavbro A, et al. Pharmacokinetic variability of drugs used for prophylactic treatment of migraine[J]. Cns Drugs, 2017, 31(5):389-403.
[16] 秦慧兵. 川芎清脑颗粒联合氟桂利嗪治疗偏头痛疗效及对患者ET-1、5-HT、CGRP水平的影响[J]. 陕西中医. 2018，39（9)：1244-1246.

更新日期/Last Update: 2019-04-10